Investment mania around a new family of drugs that purportedly offer a miracle cure for obesity has made some pharmaceutical companies into supergiants.
While the TGA has stressed a link is yet to be established,experts say it’s a reminder that Ozempic is a medicine and “not meant to be thrown around to lose a few kilograms here or there”.
If the average airline passenger lost 4.5 kilos,it would trim more than 800 kilograms from every flight,implying savings of 27.6 million gallons of jet-fuel a year.
Novo Nordisk,the Danish company behind two blockbuster obesity medications,is reaping huge profits and is now responsible for most of Denmark’s economic growth.
Mounjaro is an injectable drug made by pharmaceutical giant Eli Lilly,internationally touted as the latest medication transforming weight loss.
TikTok’s latest wellness trend says paying attention to your hormones is key to everything from weight loss to clear skin.
Doctors are sceptical of the body positivity movement and carry stigmas,new research has shown,as advocates call on GPs to avoid discussing kilos over habits.
Advertising prescription medicines is illegal in Australia. The regulator is probing whether a start-up spruiking a weight-loss drug via email falls foul of the law.
From Ozempic to a new balloon-in-a-pill,expensive treatments offer people a “fix” for obesity while the real culprits face no consequences.
The decision will see 73 stores shuttered and 306 employees lose their jobs,with Woolworths-backed healthcare start-up Eucalyptus to buy its online capability.
The Medical Board of Australia is expected to tighten its rules for telehealth companies.